BACKGROUND: Patients in phase 1 clinical trials often have significant symptom burdens and quality-of-life concerns that increase as they progress along the cancer trajectory and experience drug toxicities from the clinical trial. . OBJECTIVES: The interdisciplinary intervention described is aimed at providing optimum palliative care to support patients with solid tumors participating in a phase 1 clinical trial. . METHODS: The intervention includes a baseline evaluation using quantitative surveys, a comprehensive palliative care assessment by a research nurse based on patient baseline evaluation, and a goals-of-care discussion by the treating oncologist. The second component includes an interdisciplinary meeting where palliative care recommendations are made, followed by two patient education sessions. . FINDINGS: The initial experience with the palliative care intervention suggests a need for support for this population, as well as potential benefits from integrating palliative care for patients enrolled in phase 1 clinical trials.
BACKGROUND:Patients in phase 1 clinical trials often have significant symptom burdens and quality-of-life concerns that increase as they progress along the cancer trajectory and experience drug toxicities from the clinical trial. . OBJECTIVES: The interdisciplinary intervention described is aimed at providing optimum palliative care to support patients with solid tumors participating in a phase 1 clinical trial. . METHODS: The intervention includes a baseline evaluation using quantitative surveys, a comprehensive palliative care assessment by a research nurse based on patient baseline evaluation, and a goals-of-care discussion by the treating oncologist. The second component includes an interdisciplinary meeting where palliative care recommendations are made, followed by two patient education sessions. . FINDINGS: The initial experience with the palliative care intervention suggests a need for support for this population, as well as potential benefits from integrating palliative care for patients enrolled in phase 1 clinical trials.
Authors: Glenn B Zaide; Renee Pekmezaris; Christian N Nouryan; Tanveer P Mir; Cristina P Sison; Tara Liberman; Martin L Lesser; Lynda B Cooper; Gisele P Wolf-Klein Journal: Palliat Support Care Date: 2012-07-06
Authors: Jennifer S Temel; Joseph A Greer; Sonal Admane; Emily R Gallagher; Vicki A Jackson; Thomas J Lynch; Inga T Lennes; Connie M Dahlin; William F Pirl Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: Frederick J Meyers; John Linder; Laurel Beckett; Scott Christensen; Joan Blais; David R Gandara Journal: J Pain Symptom Manage Date: 2004-12 Impact factor: 3.612
Authors: Sydney Morss Dy; Steven M Asch; Karl A Lorenz; Kristina Weeks; Rashmi K Sharma; Antonio C Wolff; Jennifer L Malin Journal: J Palliat Med Date: 2011-03-10 Impact factor: 2.947
Authors: Esmé Finlay; Hien L Lu; Hope R Henderson; Hope Henderson; Peter J O'Dwyer; David J Casarett Journal: Cancer Date: 2009-01-15 Impact factor: 6.860
Authors: R Berman; A Davies; T Cooksley; R Gralla; L Carter; E Darlington; F Scotté; C Higham Journal: Clin Oncol (R Coll Radiol) Date: 2020-08-16 Impact factor: 4.126